Abiomed
Abiomed Announces First FDA-Approved Abiocor® Implant more

Abiomed Receives 510(k) Clearance from FDA for Impella 2.5 Device  more

Acura Pharmaceuticals
Clinical results report on Acurox reported by BioCentury Part II (pdf)  more

Acura Pharmaceuticals' double blind, placebo-controlled Phase III trial shows Acurox met primary endpoint of significant difference in pain intensity vs placebo (pdf)  more

Acura Pharmaceuticals, Inc. Announces Notice of Issuance for Patent  more

ATS Medical
ATS Medical Announces Fourth Quarter 2008 Results moremore

ATS Medical Announces $20M in Proceeds from a Private Equity Financing moremore

BioForm Medical
FQ4: Taking Share and Squashing Any Lingering Sustainability Concerns more

Merz to Acquire BioForm Medical   more

One Million Syringes of Radiesse^® Dermal Filler Have Been Shipped  more

Radiesse^® Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers  more

Radiesse^® Provides Greater Patient Satisfaction Than Either Juvederm or Perlane  more

BioForm Announces Financial Results for Quarter Ended September 30, 2007, First Quarter of Fiscal 2008  more

BioForm Strengthens Management Team with Three Leading Industry Executives  more

Bledsoe
Bledsoe Announces Partnership to Drive Growth (pdf) more

Catalyst Biosciences
Catalyst Biosciences Announces Agreement with MediImmune to Discover, Develop Engineered Protease Therapeutics more

Catalyst Biosciences Raises $40M in Series C Funding more

Ception Therapeutics
Cephalon Completes Acquisition of Ception Therapeutics (pdf) more

Cephalon Exercises its Option to Acquire Ception Therapeutics (pdf) more

Cephalon Signs Option Agreement to Acquire Ception Therapeutics more

Ception Therapeutics Initiates Phase II/III Clinical Trial for its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children more

Ception Closes Year's 2nd Largest Biopharm Round (pdf) more

Ception Therapeutics Raises $63M in Series C Financing (pdf) more

Chroma Therapeutics
GSK and Chroma Therapeutics Form Alliance to Develop Novel Macrophage Targeted Drugs That Could Result in Excess of $1B of Milestones and Option Payments to Chroma more

Chroma Therapeutics Completes £15M Series D Financing more

Chroma Announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat more

Chroma Announces Positive Phase I Efficacy Data For Novel Cancer Therapy CHR-2797( pdf) more

Complete Genomics
Complete Genomics Tops Private Biomedicine List in MIT's Technology Review's 50 Most Innovative Companies more

Complete Genomics Secures $45M in Series D Funding; Appoints Two New Directors more

Dow Pharmaceutical
Valeant to Acquire Dow Pharmaceutical Sciences for $285M morem

Elusys
Elusys Awarded $40.6M to Fund Advanced Development of Anthim more

Elusys Therapeutics Receives US Government Contract for up to $143M to Speed Up Anthrax Drug Development more

Elusys' Anthim Dramatically Improves Survival Of Animals Treated After Active Anthrax Infection  more

Elusys Announces Collaborative Research and License Agreement with Pfizer (pdf)  more

Elusys and US Army Extend Biodefense Collaboration (pdf)  more

Entellus Medical
Entellus Medical's FinESS Sinus Treatment System wins Medical Design Excellence Award more

Entellus Medical® Secures $30M Financing to Expand Commercialization of Novel Treatment for Sinusitis more

EUSA Pharma
Strategies of a Specialty Company: EUSA Pharma CEO Bryan Morton's Interview on PharmaVentures  view video

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen   more

EUSA: Powering to be the Next Shire?   more

EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to Glaxosmithkline for up to $44 Million Plus Royalties  more

EUSA Pharma Announces $30 Million Debt Facilty  more

EUSA Pharma Acquires Assets of Innocoll, Inc. (pdf)  more

Genentech
Macular Degeneration a Key Topic for Retinal Specialists more

Genentech Uses Complete Genomics' Human Genome Sequencing Service to Compare Tumor and Normal Genome more more

Healthcare Brands International
Healthcare Brands International Announces Acquisition of Antula Holdings AB more

Horizon Therapeutics
Horizon Pharma, Inc. Files Registration Statement for Proposed IPO more

Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA® more

Horizon Therapeutics: Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints more

Horizon Therapeutics and NITEC Pharma Complete Merger, Combine Businesses   more

Horizon Therapeutics Names Timothy P Walbert as President and CEO  more

Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501  more

Horizon Therapeutics Completes $30M Equity Financing  more

InSound Medical
InSound® Medical Acquired by Sonova. more

Raves (Yes, It's True) for New Hearing Aid  more

Iomai
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation  more

Iomai Wins Department of Defense Grant to Develop a Stable, Patch-based Anthrax Vaccine more

Merck to Test Iomai Patch for Boosting Vaccine Immunity  more

Iomai Awarded Government Contract, Totaling $128 Million, to Develop Dose-Sparing Patch for Use in an Influenza Pandemic  more

LaJolla Pharmaceutical
Biomarin and LaJolla Pharmaceutical Sign Agreement for Riquent more

LifeCell
KCI to Acquire LifeCell for $1.7B in Cash, Creating a Global Medical Technology Leader  more

Light Sciences Oncology
Light Sciences Oncology Meets a Major Milestone in Aptocine Development (pdf)

First Pediatric Patient Treated with Apticine^TM, a Novel Light-Activated Drug, in Neurofibromatosis Study more

Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx more

Light Sciences Oncology Raises $40.1M in Series C Financing  more

Light Sciences Oncology, Led by CEO on the Go, Prepares for Its Big Day   more

LipoSonix
LipoSonix, maker of fat-busting ultrasound, sold for $150M or more  more

Millennium Pharmacy Systems
Millennium Pharmacy Systems, MidCap Financial Close New $35M Senior Credit Facility more

Molecular Partners
Molecular Partners Secures CHF $46M in Series B Financing Led by EWHV more

Nellix
VCs Eyeing New Treatments For 'Silent Killer (PDF) more

NeoVista
NeoVista®, Inc. Receives CE Mark Approval for VIDION® ANV®®Therapy System more

NeoVista Sticks with Insiders for Series D more

Open Monoclonal Technology
OMT Announces Breakthrough in Development of a Novel Human Antibody Platform more

Oraya Therapeutics
Oraya awarded CE mark for IRay system (page 7) (pdf)

Oraya Therapeutics Raises $42M in Series C
Financing more

Oraya Therapeutics Names Jim Taylor as President and Chief Executive Officer more

Orthovita
Orthovita Receives FDA Clearance for CORTESS™ Bone Augmentation Material more

Prism Pharmaceuticals
Prism Pharmaceuticals Receives FDA Approval of NEXTERONE morem

Proteus Biomedical
NHS to Test "Intelligent Medicines" more

Proteus: The Doctor Is Out, but New Patient Monitoring and Robotics Technology Is In more

Proteus Biomedical Raises $32M in Series D Funding (PDF)   more

QSpex Technologies
QSpex Technologies Secures $12M
in Series B Funding; Appoints New Director more

Revance Therapeutics
Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type A for Facial Wrinkle Treatment more

Revance Announces Series C Expansion more Medicis and Revance Announce Strategic Collaboration more

StrataGent
StrataGent Life Sciences, Inc. Closes $16M Series B Financing  more

Symphogen
Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US more

Symphogen Appoints Adriann Sax Chief Business Officer more

Symphogen Adds Receptor's Pan-HER Ligand Trap to Diversify Recombinant Polyclonal Antibody Portfolio more

Symphogen Secures € 33M Financing to Support Clinical Development of Antibody Products more

Symphogen to Present Positive Preclinical Data on Sym004 Program more

Symphogen Raises Equity in Genentech Collab Deal  more Symphogen Issued Patent Covering Symplex™ Technology for Antibody Discovery  more

Symphogen to Present Positive Preclinical Data on Sym003 Program for RSV Infection  more

Tearscience
Tearscience®, Inc. Secures $44.5M to Commercialize Breakthrough Treatment for Dry Eye more

Thermage
Solta, Alma Lasers, Settle Thermage Patent Lawsuits more

Xanodyne Pharmaceuticals

Xanodyne Inks Drug Promotion Deal With Ferring Pharma  more

Xanodyne Divests Lysteda To Focus On Pain Market  more

Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding (pdf)  more

Xanodyne Receives Approvable Letter from the US Food and Drug Administration for ZIPSOR^TM (diclofenac potassium) Capsules (pdf)

Ziopharm
Ziopharm Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors   more

PORTFOLIO COMPANIES NEWS